Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Positron Emission Tomography scan Imaging · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Positron Emission Tomography (PET) scan Imaging | PROCEDURE | - |
Inclusion Criteria: * Male or female * Histologically proven, resected lung cancer of the following histologic types: * squamous cell carcinoma; * adenocarcinoma; * undifferentiated large cell carcinoma; * non-small cell; and * not otherwise specified. * Age equal to or greater than 18 y...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Positron Emission Tomography scan Imaging is used in lung neoplasms to aid in treatment planning for patients with non-small cell lung cancer. It is studied as part of a protocol that combines 18F-fluorodeoxyglucose imaging with three-dimensional conformal radiation therapy guided by breath-held CT and PET imaging.
Positron Emission Tomography scan Imaging is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol ALBT.
Positron Emission Tomography scan Imaging is in Phase 2 clinical development. It is an investigational agent and has not been approved by regulatory authorities. The Phase 2 trial has been completed, with 23 patients enrolled.
Positron Emission Tomography scan Imaging has one completed Phase 2 clinical trial, identified as NCT00123747. The study evaluated 18F-fluorodeoxyglucose (FluGlucoScan) in patients receiving treatment planning for three-dimensional conformal radiation therapy guided by breath-held CT and PET imaging for non-small cell lung cancer.
Positron Emission Tomography scan Imaging is associated with the tracer 18F-fluorodeoxyglucose, which is also referred to as FluGlucoScan in the clinical trial. The study NCT00123747 uses this tracer for PET imaging in lung cancer patients.